United States Biotechnology & Medical Research

CAMP4 Therapeutics Corp (CAMP)

Track

Track

CAMP4 Therapeutics Corp experienced twelve insider trading transactions recently. While executives purchased shares totaling approximately $99,051, significant selling activity reached $2,512,312. These movements occurred following the latest earnings report, where the firm beat expectations by 8.33%. The stock price has declined 7.5% over the past ninety days amid this mixed internal activity.
Ticker: CAMP Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for CAMP4 Therapeutics Corp. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Gold Kelly Chief Financial Officer Officer
Transaction date
Purchase
Price
406.29
Quantity 59,442 -42.7%
Value US$547,102
1.4
Schwab Andrew J. Non-Executive Director
Transaction date
Sale
Price
418.41
Quantity 99,531 -12.7%
Value US$1,587,765
1.4
Schwab Andrew J. Non-Executive Director
Transaction date
Sale
Price
146.62
Quantity 82,813 +8.4%
Value US$4,877,554
1.4
Schwab Andrew J. Non-Executive Director
Transaction date
Sale
Price
4.50
Quantity 32,018 -1.3%
Value US$144,081
1.4
Schwab Andrew J. Non-Executive Director
Transaction date
Sale
Price
4.54
Quantity 114,700 -4.4%
Value US$520,738
1.4
Schwab Andrew J. Non-Executive Director
Transaction date
Sale
Price
4.76
Quantity 45,147 -1.7%
Value US$214,900
Tardiff Daniel Chief Scientific Officer Officer
Transaction date
Planned sale
Price
4.76
Quantity 1,738 -100.0%
Value US$8,273
Daniel Tardiff affiliate
Transaction date
Proposed sale
Price
4.76
Quantity 1,738
Value US$8,276
Maricich Yuri Chief Medical Officer Officer
Transaction date
Purchase
Price
1.65
Quantity 6,551 +108.1%
Value US$10,809
Young Richard A Non-Executive Director
Transaction date
Purchase
Price
1.65
Quantity 16,378 +9.6%
Value US$27,024
Gold Kelly Chief Financial Officer Officer
Transaction date
Purchase
Price
1.65
Quantity 6,551 +9.7%
Value US$10,809
Mandel-Brehm Josh Chief Executive Officer Executive Director
Transaction date
Purchase
Price
1.65
Quantity 6,551 +2.4%
Value US$10,809
2.6
5AM Partners VI, LLC Large shareholder
Transaction date
Purchase
Price
1.53
Quantity 2,941,176 +inf%
Value US$4,499,999
2.5
Nashat Amir Non-Executive Director Large shareholder
Transaction date
Purchase
Price
1.53
Quantity 85,468 +76.2%
Value US$130,766
2.5
Nashat Amir Non-Executive Director Large shareholder
Transaction date
Purchase
Price
1.53
Quantity 1,221,721 +76.2%
Value US$1,869,233
Maricich Yuri Chief Medical Officer Officer
Transaction date
Purchase
Price
1.65
Quantity 6,060 +inf%
Value US$9,999
Mandel-Brehm Josh Chief Executive Officer Executive Director
Transaction date
Purchase
Price
1.65
Quantity 6,060 +2.2%
Value US$9,999
Young Richard A Non-Executive Director
Transaction date
Purchase
Price
1.65
Quantity 15,151 +9.8%
Value US$24,999
Gold Kelly Chief Financial Officer Officer
Transaction date
Purchase
Price
1.65
Quantity 6,060 +9.8%
Value US$9,999
1.4
Enavate Sciences GP, LLC Large shareholder
Transaction date
Purchase
Price
11.00
Quantity 1,363,636 +56.3%
Value US$14,999,996
1.4
Schwab Andrew J. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.00
Quantity 909,090 +53.0%
Value US$9,999,990
2.5
Nashat Amir Non-Executive Director Large shareholder
Transaction date
Purchase
Price
11.00
Quantity 909,090 +inf%
Value US$9,999,990
2.6
5AM Partners VI, LLC Large shareholder
Transaction date
Purchase
Price
11.00
Quantity 909,090 +53.0%
Value US$9,999,990
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-02 2026-08-31 B Purchase
Gold Kelly

Chief Financial Officer

Officer
59,442 -42.7%
406.29
US$547,102 		59,442 -42.7% 406.29 US$547,102
2026-08-31 2026-08-27 S Sale
1.4
Schwab Andrew J.
Non-Executive Director
99,531 -12.7%
418.41
US$1,587,765 		99,531 -12.7% 418.41 US$1,587,765
2026-08-26 2026-08-24 S Sale
1.4
Schwab Andrew J.
Non-Executive Director
82,813 +8.4%
146.62
US$4,877,554 		82,813 +8.4% 146.62 US$4,877,554
2026-08-21 2026-08-21 S Sale
1.4
Schwab Andrew J.
Non-Executive Director
32,018 -1.3%
4.50
US$144,081 		32,018 -1.3% 4.50 US$144,081
2026-08-21 2026-08-20 S Sale
1.4
Schwab Andrew J.
Non-Executive Director
114,700 -4.4%
4.54
US$520,738 		114,700 -4.4% 4.54 US$520,738
2026-08-21 2026-08-19 S Sale
1.4
Schwab Andrew J.
Non-Executive Director
45,147 -1.7%
4.76
US$214,900 		45,147 -1.7% 4.76 US$214,900
2026-08-19 2026-08-19 PlS Planned sale
Tardiff Daniel

Chief Scientific Officer

Officer
1,738 -100.0%
4.76
US$8,273 		1,738 -100.0% 4.76 US$8,273
2026-08-19 2026-08-19 PrS Proposed sale
Daniel Tardiff

affiliate
1,738
4.76
US$8,276 		1,738 4.76 US$8,276
2026-08-05 2026-08-03 B Purchase
Maricich Yuri

Chief Medical Officer

Officer
6,551 +108.1%
1.65
US$10,809 		6,551 +108.1% 1.65 US$10,809
2026-08-05 2026-08-03 B Purchase
Young Richard A
Non-Executive Director
16,378 +9.6%
1.65
US$27,024 		16,378 +9.6% 1.65 US$27,024
2026-08-05 2026-08-03 B Purchase
Gold Kelly

Chief Financial Officer

Officer
6,551 +9.7%
1.65
US$10,809 		6,551 +9.7% 1.65 US$10,809
2026-08-05 2026-08-03 B Purchase
Mandel-Brehm Josh

Chief Executive Officer

Executive Director
6,551 +2.4%
1.65
US$10,809 		6,551 +2.4% 1.65 US$10,809
2025-09-15 2025-09-11 B Purchase
2.6
5AM Partners VI, LLC
Large shareholder
2,941,176 +inf%
1.53
US$4,499,999 		2,941,176 +inf% 1.53 US$4,499,999
2025-09-11 2025-09-11 B Purchase
1.8
Polaris Management Co. VII, L.L.C.
Large shareholder
85,468 +76.2%
1.53
US$130,766 		85,468 +76.2% 1.53 US$130,766
2025-09-11 2025-09-11 B Purchase
1.8
Polaris Management Co. VII, L.L.C.
Large shareholder
1,221,721 +76.2%
1.53
US$1,869,233 		1,221,721 +76.2% 1.53 US$1,869,233
2025-09-11 2025-09-11 B Purchase
2.5
Nashat Amir
Non-Executive Director Large shareholder
85,468 +76.2%
1.53
US$130,766 		85,468 +76.2% 1.53 US$130,766
2025-09-11 2025-09-11 B Purchase
2.5
Nashat Amir
Non-Executive Director Large shareholder
1,221,721 +76.2%
1.53
US$1,869,233 		1,221,721 +76.2% 1.53 US$1,869,233
2025-09-11 2025-09-11 B Purchase
Maricich Yuri

Chief Medical Officer

Officer
6,060 +inf%
1.65
US$9,999 		6,060 +inf% 1.65 US$9,999
2025-09-11 2025-09-11 B Purchase
Mandel-Brehm Josh

Chief Executive Officer

Executive Director
6,060 +2.2%
1.65
US$9,999 		6,060 +2.2% 1.65 US$9,999
2025-09-11 2025-09-11 B Purchase
Young Richard A
Non-Executive Director
15,151 +9.8%
1.65
US$24,999 		15,151 +9.8% 1.65 US$24,999
2025-09-11 2025-09-11 B Purchase
Gold Kelly

Chief Financial Officer

Officer
6,060 +9.8%
1.65
US$9,999 		6,060 +9.8% 1.65 US$9,999
2024-10-17 2024-10-15 B Purchase
0.5
AH Equity Partners Bio I, L.L.C.
Large shareholder
545,454 +inf%
11.00
US$5,999,994 		545,454 +inf% 11.00 US$5,999,994
2024-10-17 2024-10-15 B Purchase
0.5
AH Equity Partners Bio I, L.L.C.
Large shareholder
181,818 +13.0%
11.00
US$1,999,998 		181,818 +13.0% 11.00 US$1,999,998
2024-10-17 2024-10-15 B Purchase
0.5
Northpond Ventures II GP, LLC
Large shareholder
763,636 +inf%
11.00
US$8,399,996 		763,636 +inf% 11.00 US$8,399,996
2024-10-17 2024-10-15 B Purchase
1.4
Enavate Sciences GP, LLC
Large shareholder
1,363,636 +56.3%
11.00
US$14,999,996 		1,363,636 +56.3% 11.00 US$14,999,996
2024-10-15 2024-10-15 B Purchase
1.4
Schwab Andrew J.
Non-Executive Director Large shareholder
909,090 +53.0%
11.00
US$9,999,990 		909,090 +53.0% 11.00 US$9,999,990
2024-10-15 2024-10-15 B Purchase
2.5
Nashat Amir
Non-Executive Director Large shareholder
909,090 +inf%
11.00
US$9,999,990 		909,090 +inf% 11.00 US$9,999,990
2024-10-15 2024-10-15 B Purchase
1.8
Polaris Management Co. VII, L.L.C.
Large shareholder
909,090 +inf%
11.00
US$9,999,990 		909,090 +inf% 11.00 US$9,999,990
2024-10-15 2024-10-15 B Purchase
2.6
5AM Partners VI, LLC
Large shareholder
909,090 +53.0%
11.00
US$9,999,990 		909,090 +53.0% 11.00 US$9,999,990
Explore more

More insider trading research around CAMP4 Therapeutics Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America